Vamshi K. Rao

Vamshi K. Rao

Auto-generated profile, based on publicly available information

Vamshi K. Rao

Division of Neurology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in JAMA Neurology
Verified
Journal Article
Closed access
PDF file
PCPaula R. Clemens
Paula R. Clemens
VRVamshi K. Rao
Vamshi K. Rao
ACAnne M. Connolly
Anne M. Connolly
AHAmy D. Harper
Amy D. Harper
JMJean K. Mah
Jean K. Mah
FIfor the CINRG DNHS Investigators
for the CINRG DNHS Investigators
Duchenne muscular dystrophy (DMD) is an X-linked disorder affecting approximately 1 in 3500 to 5000 live male births.1-3 Progressive weakness and skeletal muscle degeneration are caused by an absence of functional dystrophin protein secondary to loss-of-function variants in the DMD gene.1,4 Patients with DMD typically exhibit dystrophin levels less than 3% of normal.5 Dystrophin deficiency in DMD leads to progressive disability and early death owing to respiratory failure and cardiac dysfunction.1,6 Patients with Becker muscular dystrophy (BMD) exhibit in-frame deletions in DMD that allow for production of partially functional truncated dystrophin, with later onset, decreased severity, and slower disease progression compared with patients with DMD.7

17 February 2016 in Brain
Verified
Journal Article
Open access
PDF file
SBSusan Byrne
Susan Byrne
LJLara Jansen
Lara Jansen
JUJean-Marie U-King-Im
Jean-Marie U-King-Im
ASAta Siddiqui
Ata Siddiqui
HLHart G. W. Lidov
Hart G. W. Lidov
HJHeinz Jungbluth
Heinz Jungbluth
Vici syndrome is a progressive neurodevelopmental multisystem disorder due to recessive mutations in the key autophagy gene EPG5. We report genetic, clinical, neuroradiological, and neuropathological features of 50 children from 30 families, as well as the neuronal phenotype of EPG5 knock-down in Drosophila melanogaster. We identified 39 different EPG5 mutations, most of them truncating and predicted to result in reduced EPG5 protein. Most mutations were private, but three recurrent mutations (p.Met2242Cysfs*5, p.Arg417*, and p.Gln336Arg) indicated possible founder effects. Presentation was mainly neonatal, with marked hypotonia and feeding difficulties. In addition to the five principal features (callosal agenesis, cataracts, hypopigmentation, cardiomyopathy, and immune dysfunction), we identified three equally consistent features (profound developmental delay, progressive microcephaly, and failure to thrive). The manifestation of all eight of these features has a specificity of 97%, and a sensitivity of 89% for the presence of an EPG5 mutation and will allow informed decisions about genetic testing. Clinical progression was relentless and many children died in infancy. Survival analysis demonstrated a median survival time of 24 months (95% confidence interval 0–49 months), with only a 10th of patients surviving to 5 years of age. Survival outcomes were significantly better in patients with compound heterozygous mutations (P = 0.046), as well as in patients with the recurrent p.Gln336Arg mutation. Acquired microcephaly and regression of skills in long-term survivors suggests a neurodegenerative component superimposed on the principal neurodevelopmental defect. Two-thirds of patients had a severe seizure disorder, placing EPG5 within the rapidly expanding group of genes associated with early-onset epileptic encephalopathies. Consistent neuroradiological features comprised structural abnormalities, in particular callosal agenesis and pontine hypoplasia, delayed myelination and, less frequently, thalamic signal intensity changes evolving over time. Typical muscle biopsy features included fibre size variability, central/internal nuclei, abnormal glycogen storage, presence of autophagic vacuoles and secondary mitochondrial abnormalities. Nerve biopsy performed in one case revealed subtotal absence of myelinated axons. Post-mortem examinations in three patients confirmed neurodevelopmental and neurodegenerative features and multisystem involvement. Finally, downregulation of epg5 (CG14299) in Drosophila resulted in autophagic abnormalities and progressive neurodegeneration. We conclude that EPG5-related Vici syndrome defines a novel group of neurodevelopmental disorders that should be considered in patients with suggestive features in whom mitochondrial, glycogen, or lysosomal storage disorders have been excluded. Neurological progression over time indicates an intriguing link between neurodevelopment and neurodegeneration, also supported by neurodegenerative features in epg5-deficient Drosophila, and recent implication of other autophagy regulators in late-onset neurodegenerative disease.

1 November 2004 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
NTNilesh S. Tannu
Nilesh S. Tannu
VRVamshi K. Rao
Vamshi K. Rao
RCRitcha M. Chaudhary
Ritcha M. Chaudhary
FGFrancesco Giorgianni
Francesco Giorgianni
ASAbdelwahab E. Saeed
Abdelwahab E. Saeed
RRRajendra Raghow
Rajendra Raghow
When cultured in low serum-containing growth medium, the mouse C2C12 cells exit cell cycle and undergo a well-defined program of differentiation that culminates in the formation of myosin heavy chain-positive bona fide multinucleated muscle cells. To gain an understanding into this process, we compared total, membrane- and nuclear-enriched proteins, and phospho-proteins from the proliferating C2C12 cells and the fully differentiated myotubes by the combined methods of two-dimensional PAGE, quantitative PDQuest image analysis, and MS. Quantification of more than 2,000 proteins from C2C12 myoblasts and myotubes revealed that a vast majority of the abundant proteins appear to be relegated to the essential, housekeeping and structural functions, and their steady state levels remain relatively constant. In contrast, 75 proteins were highly regulated during the phenotypic conversion of rapidly dividing C2C12 myoblasts into fully differentiated, multi-nucleated, post-mitotic myotubes. We found that differential accumulation of 26 phospho-proteins also occurred during conversion of C2C12 myoblasts into myotubes. We identified the differentially expressed proteins by MALDI-TOF-MS and LC-ESI-quadrupole ion trap MS/MS. We demonstrate that more than 100 proteins, some shown to be associated with muscle differentiation for the first time, that regulate inter- and intracellular signaling, cell shape, proliferation, apoptosis, and gene expression impinge on the mechanism of skeletal muscle differentiation.

29 December 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SHSuzan M. Hammond
Suzan M. Hammond
RGRocky G. Gogliotti
Rocky G. Gogliotti
VRVamshi Rao
Vamshi Rao
ABAriane Beauvais
Ariane Beauvais
RKRashmi Kothary
Rashmi Kothary
CDChristine J. DiDonato
Christine J. DiDonato
Spinal muscular atrophy (SMA) is caused by low survival motor neuron (SMN) levels and patients represent a clinical spectrum due primarily to varying copies of the survival motor neuron-2 (SMN2) gene. Patient and animals studies show that disease severity is abrogated as SMN levels increase. Since therapies currently being pursued target the induction of SMN, it will be important to understand the dosage, timing and cellular requirements of SMN for disease etiology and potential therapeutic intervention. This requires new mouse models that can induce SMN temporally and/or spatially. Here we describe the generation of two hypomorphic Smn alleles, SmnC-T-Neo and Smn2B-Neo. These alleles mimic SMN2 exon 7 splicing, titre Smn levels and are inducible. They were specifically designed so that up to three independent lines of mice could be generated, herein we describe two. In a homozygous state each allele results in embryonic lethality. Analysis of these mutants indicates that greater than 5% of Smn protein is required for normal development. The severe hypomorphic nature of these alleles is caused by inclusion of a loxP-flanked neomycin gene selection cassette in Smn intron 7, which can be removed with Cre recombinase. In vitro and in vivo experiments demonstrate these as inducible Smn alleles. When combined with an inducible Cre mouse, embryonic lethality caused by low Smn levels can be rescued early in gestation but not late. This provides direct genetic evidence that a therapeutic window for SMN inductive therapies may exist. Importantly, these lines fill a void for inducible Smn alleles. They also provide a base from which to generate a large repertoire of SMA models of varying disease severities when combined with other Smn alleles or SMN2-containing mice.

25 July 2020 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
YHYohei Harada
Yohei Harada
VRVamshi K. Rao
Vamshi K. Rao
KAKapil Arya
Kapil Arya
NKNancy Kuntz
Nancy Kuntz
CDChristine J. DiDonato
Christine J. DiDonato
AVAravindhan Veerapandiyan
Aravindhan Veerapandiyan

1 April 2004 in Analytical Biochemistry
Verified
Journal Article
Closed access
NTNilesh S Tannu
Nilesh S Tannu
JWJian Wu
Jian Wu
VRVamshi K Rao
Vamshi K Rao
HGHimanshu S Gadgil
Himanshu S Gadgil
MPMichael J Pabst
Michael J Pabst
RRRajendra Raghow
Rajendra Raghow